Transcription factors in chimeric antigen receptor T-cell development

Hum Cell. 2024 May;37(3):571-581. doi: 10.1007/s13577-024-01040-7. Epub 2024 Mar 4.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a new and innovative approach to treating cancers that has shown promising results in the treatment of lymphoma. However, it has been found to be less effective in the treatment of solid tumors. To overcome the limitation, researchers have explored the use of combined CAR-T therapy with other complementary regimens that target specific genes or biomarkers, which would enhance the synergistic therapeutic effects. Transcription factors (TFs) have been identified as potential markers that can regulate gene expression in CAR-T cells to enhance their cytotoxicity and safety. TFs are known to bind DNA specifically and recruit cofactor proteins to regulate the expression of target genes. By targeting TFs, it is possible to improve the anti-tumor response of CAR-T cells by altering their phenotype and transcriptional map, thereby increasing their effector function, such as reducing the exhaustion, enhancing the survival, and cytotoxicity of CAR-T cells. This review summarizes the application of transcription factors in CART therapy to enhance the synergistic therapeutic effect of CAR-T cells in the treatment of solid tumors and improve their anti-tumor responses.

Keywords: CART; Solid tumors; Transcription factors.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy, Adoptive / methods
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Receptors, Chimeric Antigen* / genetics
  • Receptors, Chimeric Antigen* / metabolism
  • T-Lymphocytes / metabolism
  • Transcription Factors / genetics
  • Transcription Factors / metabolism

Substances

  • Receptors, Chimeric Antigen
  • Transcription Factors